Search

Displaying results 4011 - 4020 of 6198 in total
  1. Drug

    Panitumumab

    go.drugbank.com/drugs/DB01269
    ApprovedInvestigational

    This drug is an antineoplastic agent. Panitumumab was granted FDA approval on 27 September 2006.[L17663]

  2. Drug

    Gluconolactone

    go.drugbank.com/drugs/DB04564
    Approved

    Gluconolactone is a naturally-occurring food additive used as a sequestrant, an acidifier, or a curing, pickling, or leavening agent. It is a cyclic ester of D-gluconic acid.

  3. Drug

    Bicalutamide

    go.drugbank.com/drugs/DB01128
    ApprovedInvestigational

    Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers.

    Products: Van-bicalutamide, Ran-bicalutamide
  4. Drug

    AME-527

    go.drugbank.com/drugs/DB05879
    Experimental

    AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties.

  5. Indication

    Squamous Cell Carcinoma In-situ (SCC-is)

    go.drugbank.com/conditions/DBCOND0043487
    Drugs: Aminolevulinic acid
    Synonyms: (Basal cell carcinoma) or (Bowen's disease) or (rodent ulcer) or (skin Ca - excluding melanoma) or (Ca skin - other)
  6. Drug

    Rubella virus vaccine

    go.drugbank.com/drugs/DB10317
    ApprovedInvestigational

    Rubella is a common childhood disease, caused by rubella virus (togavirus).

  7. Drug

    Olmutinib

    go.drugbank.com/drugs/DB13164
    Investigational

    It is available under the brand name Olita made by Hanmi Pharmaceuticals [A19196]. Olmutinib was developed by Hanmi Pharmaceuticals and Boehringer Ingelheim. … Olmutinib is an orally active epidermal growth factor receptor inhibitor used in the treatment of T790M mutation positive non-small cell lung cancer.

  8. Drug

    M0002

    go.drugbank.com/drugs/DB05091
    Investigational

    M0002 is an orally-active selective vasopressin antagonist that inhibits water re-absorption from the kidneys.

  9. Drug

    Acadesine

    go.drugbank.com/drugs/DB04944
    Investigational

    It is being developed jointly by PeriCor and Schering-Plough. Acadesine has been granted Orphan Drug Designation for B-CLL in the EU.

  10. Drug

    Pipamperone

    go.drugbank.com/drugs/DB09286
    Investigational

    It was developed by Janssen Pharmaceutica in 1961 and started its first round of clinical trials in 1963 [L1514, L1518]. … In an effort to improve [haloperidol]'s pharmacological effects, Janssen discovered that pipamperone, an agent whose pharmacological profile was distinct from haloperidol and all other known antipsychotic